How Much Weight Can You Lose on Retatrutide? Trial Results Explained

Retatrutide has produced some of the largest weight loss of any drug in development, reaching roughly 24% in mid-stage trials and climbing toward 30% in later, longer studies, approaching what bariatric surgery achieves. It’s a triple agonist, and this level of weight loss is the main reason it’s considered one of the most promising obesity drugs in the pipeline. Retatrutide is investigational and not FDA approved. Here’s what the trials actually showed and how to interpret the numbers.

The Phase 2 Result That Started the Buzz

Retatrutide first drew major attention with a phase 2 trial published in the New England Journal of Medicine in 2023, which studied it in adults with obesity and found that the highest dose produced about 24% average weight loss at 48 weeks. That figure was striking because it exceeded what approved drugs like semaglutide (around 15%) and tirzepatide (up to about 21%) had shown, positioning retatrutide as potentially the most powerful option yet. Just as notably, the weight loss hadn’t plateaued at 48 weeks, hinting that longer treatment could push it higher.

The Phase 3 Numbers

That hint proved accurate. Topline results from the pivotal phase 3 trial (TRIUMPH-1), announced in 2026, showed even larger weight loss over a longer 80-week period. At the highest dose, participants lost up to about 28% of their body weight, and a meaningful share (over 40%) lost at least 30%. In a study extension following people with more severe obesity out to 104 weeks, average weight loss reached up to about 30%.

Even the lower 4 mg dose produced about 19% weight loss, which is competitive with the strongest approved drugs, while offering a gentler option.

What “Bariatric-Level” Means

Weight loss near 30% is significant because it enters territory previously associated mainly with weight-loss surgery. For context, procedures like gastric bypass often produce weight loss in roughly the 25% to 35% range. A medication reaching similar numbers would represent a real shift in what’s possible without surgery. Consider a hypothetical patient who wasn’t a candidate for or didn’t want surgery: a drug delivering surgery-like weight loss would open a genuinely new option for them, which is the promise driving interest in retatrutide.

A Note on the Numbers

As with any trial, the exact figure depends on how it’s measured. The roughly 28% reflects results when people stay on treatment as intended, while a broader analysis counting everyone (including those who stopped) shows a somewhat lower figure closer to 25%. Both are impressive. It’s also worth remembering these later results are topline announcements, with full peer-reviewed publication still to come, so some details may be refined.

Frequently Asked Questions

How much weight can you actually lose on retatrutide?

In trials, the highest dose produced about 24% weight loss over 48 weeks (phase 2) and up to about 28% over 80 weeks (phase 3), reaching up to about 30% in a longer extension for people with more severe obesity. Lower doses produced correspondingly less, around 19% at the 4 mg dose.

Is retatrutide the most effective weight-loss drug?

It has shown some of the highest weight loss of any drug in development, approaching bariatric-surgery levels. Whether it’s definitively the “most effective” depends on final phase 3 data and comparisons, but it’s among the front-runners.

Is retatrutide available to lose weight now?

No. Retatrutide is investigational and not FDA approved, available only through clinical trials, though a regulatory submission is anticipated. TrimRx offers currently available options like compounded semaglutide and tirzepatide and brand GLP-1 medications instead.

To focus on what you can actually start with today, you can explore the options available to you now with a licensed provider.

This information is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA approved; details and timelines may change. Consult a healthcare provider before starting any medication. Individual results may vary.